Brief: AFT Pharmaceuticals Signs New Licence Agreements For Maxigesic Pain Relief Medicine
26/03/2023 21:23
March 27 (Reuters) - AFT Pharmaceuticals Ltd AFT.NZ :
* SIGNED FURTHER NEW LICENCE AGREEMENTS FOR INTRAVENOUS DOSE
FORM
OF ITS MAXIGESIC PAIN RELIEF MEDICINE
* CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED
CRYSTAWASH EXTEND WHICH ALLOWS CO TO SELL AT RETAIL STORES IN
CHINA
Further company coverage: AFT.NZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AFT Pharmaceuticals
See all newsNZ's AFT Pharma eyes highest weekly gain in over 2 months after results
Brief: AFT Pharmaceuticals Reports Double Digit Revenue Growth In 1H FY27
NZ's AFT Pharmaceuticals gains most in over 2 weeks on strong half-year results
Brief: AFT Pharmaceuticals Enters Exclusive Development, License And Supply Agreement With Mikasaseiyaku
NZ's AFT Pharma rises to near 1-month high on Japan licensing deal for Maxigesic IV